D
espite the lack of conclusive evidence, many neurologists feel that early aggressive management of relapsing remitting multiple sclerosis (RRMS) using DMT improve the outcome for their patients. 2 Clinical trials often use the terms 'highly active' and 'rapidly evolving severe' RRMS in their further analysis of the trial data aimed at establishing the impact of the drug examined in those two unique populations of RRMS sufferers. Highly active and rapidly evolving RRMS patients are thought to benefit most of the aggressive early management with high efficacy DMTs. 3 Many regulatory agencies, including NICE, use the same definitions for those two unique subgroups of RRMS. With problems with safety, tolerability and high cost, DMTs' routine use can be a complex process for the clinician, patient and health economist. Contrary to public perception, NICE is probably keen to welcome new DMTs hoping that Adam Smith's 'invisible hand' will force an inevitable reduction of cost by unleashing market forces. The routine use of DMTs should also encourage the emergence of more real-life data that may eventually help improve patients' outcomes.
Cladribine was first investigated in the 1970s as a preferential lymphocyte depleting therapy for treatment of lymphoid malignancies, and was initially shown to be effective in treatment of hairy cell leukaemia. 4 It has been extensively studied in other autoimmune disorders, most successfully in multiple sclerosis. Cladribine was initially approved for use in Australia in 2010 and has more recently received marketing authorisation from the European Commission in August 2017 as a DMT for RRMS patients.
Pharmacokinetics
Cladribine is a synthetic deoxyadenosine analog with selective activity against circulating T and B lymphocytes. Intracellularly, cladribine interferes with DNA synthesis and repair via inhibition of enzymes required for DNA metabolism, leading to cell death. Cladribine targets lymphocytes, which are dependent on adenosine deaminase to maintain equilibrium of triphosphorylated nucleotides. 5 Cladribine's therapeutic effect in multiple sclerosis is through a rapid and sustained depletion of CD4 and CD8 T cells with a less sustained effect on CD19 B cells. This occurs with a relative sparing of other immune cells such as neutrophils and monocytes.
Evidence
Evidence for cladribine's use in multiple sclerosis comes from the cladribine tablets treating multiple sclerosis orally (CLARITY) study. 6 This was a randomised double blind study of 1326 participants comparing cladribine with placebo. In this trial, cladribine reduced the relapse rate per year by 58%. It also demonstrated delayed disability progression over six months in comparison with placebo.
Cladribine tablets and multiple sclerosis: NICE technology appraisal Tarek Gaber FRCP, Clare Shippen MRCP Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017. 1 An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage. In the subgroup analysis, only small numbers in this trial had rapidly evolving or highly active disease not responsive to previous treatment (50 and 19 participants respectively). In these small subgroups, the effect of cladribine on disability progression became insignificant.
There are no randomised controlled trials comparing cladribine with other DMTs currently used. In a meta-analysis, cladribine has shown comparable results to other DMTs, although infusion therapies (ie alemtuzumab) were shown to have higher reduction in annual relapse rate. However, this was not statistically significant. 7 On assessment of cost-effectiveness, cladribine was found to be more cost effective and cheaper than daclizumab, fingolimod and natalizumab in the relevant subgroups with severe disease. Compared with alemtuzumab, cladribine was a less cost-effective option. 7 An extended analysis of data from the CLARITY trial also revealed that use of cladribine had a significant positive impact on quality of life indices. 8 
Medicine administration
Cladribine is given as an oral tablet over a two-year course. It is taken for five days and then repeated the next month. It is then taken in the same way the next year. No further treatment is then required in years 3 and 4 (Table 1) .
Side effects
The most common adverse event noted is of lymphopenia and this is the most common reason for treatment discontinuation. Thrombocytopenia is also a potential adverse event. In the CLARITY extension trial, 11.7% of patients experienced one serious adverse event, including infections and gastrointestinal disorders. An increased risk of herpes virus infections was noted. There were no reported cases of progressive multifocal leukoencephalopathy (PML) in patients treated with cladribine for MS. However, cases of PML have been observed in patients on cladribine for other conditions. Recommendations NICE is keen to support the use of high efficacy DMTs as early as possible for patients with highly active and rapidly evolving RRMS. Alemtuzumab remains the drug of choice for both conditions with daclizumab as an alternative if alemtuzumab use is inappropriate for a particular patient. Fingolimod is another option for highly active RRMS and natalizumab is a popular choice for rapidly evolving RRMS.
Cladribine is recommended for either highly active or rapidly evolving RRMS patients. Its cost and method of administration are clear advantages but still it seems to be less potent than alemtuzumab. As the only orally administered drug recommended for rapidly evolving RRMS, it may have a niche use in this subgroup.
Conclusions
Cladribine is the latest option in the range of medications available for treatment of severe and highly active multiple sclerosis. It has been shown in one large randomised controlled trial to reduce relapse rate and reduce disability in patients with relapsing remitting MS. There are no trials directly comparing cladribine with other DMTs. However, the evidence from meta-analysis demonstrates its efficacy is comparable with the other options available. Cladribine's main advantages are cost-effectiveness compared with other treatments, and as it is given as oral medication it could be a less disruptive treatment option. The main side effect is of lymphopenia, which can be severe and sustained, with an increased risk of infection.
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